Drug Trial Radar · NCT05988203
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Sep 21, 2023
Primary completion
Aug 25, 2025
Study completion Mar 4, 2026
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox). This study was originally planned to include four substudies, i.e., substudy A (SSA), substudy B (SSB), substudy C (SSC), and substudy D (SSD). Sponsor decided not to conduct SSC, thus three substudies (SSA, SSB, and SSD) were conducted. In SSA and SSB, dosing started with an initial sentinel group, followed by the expansion cohort. In SSD, dosing was initiated after the interim analysis of SSA and SSB 1-month post-Dose 2 safety, reactogenicity, and immunogenicity data was received. This study was initially planned to investigate two vaccine candidates (the quadrivalent BNT166a and the trivalent BNT166c). The sponsor decided to not activate the groups with BNT166c.
Conditions
- Monkeypox
Interventions
BNT166aBiological
Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Solicited Local Reactions At the Injection SiteTime frame: Up to 7 days post any vaccination, and up to 7 days post each vaccination dose (that is, post-dose 1 [up to Day 8]) and post-dose 2 [up to Day 38])
- Number of Participants Reporting Solicited Systemic EventsTime frame: Up to 7 days post any vaccination, and up to 7 days post each vaccination dose (that is, post Dose 1 [up to Day 8] and post Dose 2 [up to Day 38])
- Number of Participants With At Least One Unsolicited Adverse Event (AE)Time frame: Up to 28 days post any vaccination, and up to 28 days post each vaccination dose (that is, post-dose 1 [up to Day 29] and post-Dose 2 [up to Day 59])
- Number of Participants With At Least One Serious Adverse Event (SAE)Time frame: From Dose 1 up to Day 201
- Number of Participants With At Least One Adverse Event of Special Interest (AESI)Time frame: From Dose 1 up to Day 201
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
California Research Foundation
San Diego, California
Alliance for Multispecialty Research, LLC
Kansas City, Missouri
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee
University of Washington Virology Research Clinic
Seattle, Washington
Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Royal Surrey County Hospital Foundation Trust, NIHR Royal Surrey Clinical Research Facility
Guildford, United Kingdom
Guy's and St Thomas' NHS Foundation Trust of St Thomas' Hospital
London, United Kingdom
Medicine Evaluation Unit Ltd, The Langley Building, Wythenshawe Hospital
Manchester, United Kingdom
University Hospital Southampton
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.